Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
Search for other papers by Jan Calissendorff in
Google Scholar
PubMed
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
Search for other papers by Henrik Falhammar in
Google Scholar
PubMed
Introduction Graves’ disease (GD) is common and can be treated by medication blocking thyroid hormone synthesis with drugs such as methimazole, carbimazole or propylthiouracil. With medication for 12–18 months, cure can be achieved, which is
Search for other papers by Xichang Wang in
Google Scholar
PubMed
Search for other papers by Xiaochun Teng in
Google Scholar
PubMed
Search for other papers by Chenyan Li in
Google Scholar
PubMed
Search for other papers by Yushu Li in
Google Scholar
PubMed
Search for other papers by Jing Li in
Google Scholar
PubMed
Search for other papers by Weiping Teng in
Google Scholar
PubMed
Search for other papers by Zhongyan Shan in
Google Scholar
PubMed
Search for other papers by Yaxin Lai in
Google Scholar
PubMed
, 5 ), and hyperthyroid crisis can even be life-threatening. Treatment options for hyperthyroidism mainly include anti-thyroid drugs (ATDs), radioactive iodine (RAI) and thyroidectomy, as well as β-blockers as ancillary therapy. With the
Search for other papers by Dimitra Argyro Vassiliadi in
Google Scholar
PubMed
Search for other papers by Ioannis Ilias in
Google Scholar
PubMed
Search for other papers by Maria Pratikaki in
Google Scholar
PubMed
Search for other papers by Edison Jahaj in
Google Scholar
PubMed
Search for other papers by Alice G Vassiliou in
Google Scholar
PubMed
Search for other papers by Maria Detsika in
Google Scholar
PubMed
Search for other papers by Kleio Ampelakiotou in
Google Scholar
PubMed
Search for other papers by Marina Koulenti in
Google Scholar
PubMed
Search for other papers by Konstantinos N Manolopoulos in
Google Scholar
PubMed
Search for other papers by Stamatis Tsipilis in
Google Scholar
PubMed
Search for other papers by Evdokia Gavrielatou in
Google Scholar
PubMed
Search for other papers by Aristidis Diamantopoulos in
Google Scholar
PubMed
Search for other papers by Alexandros Zacharis in
Google Scholar
PubMed
Search for other papers by Nicolaos Athanasiou in
Google Scholar
PubMed
Search for other papers by Stylianos Orfanos in
Google Scholar
PubMed
Search for other papers by Anastasia Kotanidou in
Google Scholar
PubMed
Search for other papers by Stylianos Tsagarakis in
Google Scholar
PubMed
Search for other papers by Ioanna Dimopoulou in
Google Scholar
PubMed
' thyroiditis, anti-thyroid autoantibodies as well as interleukin-6 (IL-6) levels. Table 1 Prevalence of thyroid hormone abnormalities in patients with COVID-19 and controls in recently published studies. Month Author Design n Population
Search for other papers by Monika Schaffner in
Google Scholar
PubMed
Search for other papers by Ursula Rochau in
Google Scholar
PubMed
Search for other papers by Nikolai Mühlberger in
Google Scholar
PubMed
Search for other papers by Annette Conrads-Frank in
Google Scholar
PubMed
Faculty of Pharmacy, School of PhD Studies, Ss. Cyril and Methodius University, Skopje, Macedonia
Search for other papers by Vjollca Qerimi Rushaj in
Google Scholar
PubMed
Search for other papers by Gaby Sroczynski in
Google Scholar
PubMed
Search for other papers by Eftychia Koukkou in
Google Scholar
PubMed
Search for other papers by Betina Heinsbaek Thuesen in
Google Scholar
PubMed
Search for other papers by Henry Völzke in
Google Scholar
PubMed
Search for other papers by Wilhelm Oberaigner in
Google Scholar
PubMed
Center for Health Decision Science, Department of Health Policy and Management, Harvard Chan School of Public Health, Boston, Massachusetts, USA
Department of Radiology, Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Search for other papers by Uwe Siebert in
Google Scholar
PubMed
.g. the category anti-thyroid medication) ( 34 ). The prices for medication were based on the data from the German pharmacy price schedule (Lauer Taxe) 2018 ( 35 ). We also considered out-of-pocket costs for patients according to the regulation of the
Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Dorte Glintborg in
Google Scholar
PubMed
Search for other papers by Katrine Hass Rubin in
Google Scholar
PubMed
Search for other papers by Mads Nybo in
Google Scholar
PubMed
Department of Medicine, Holbæk Hospital, Holbæk, Denmark
Search for other papers by Bo Abrahamsen in
Google Scholar
PubMed
Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Marianne Andersen in
Google Scholar
PubMed
(Hypothyroidism (E03), struma (E04), thyrotoxicosis (E05), thyroiditis (E06), 0905 post-partum thyroiditis, iodine deficiency related thyroid disease E01, E02); or 2, prescription of drugs for treatment of thyroid disease (H03 (H03A thyroid hormone, H03B anti-thyroid
Search for other papers by Jia Liu in
Google Scholar
PubMed
Search for other papers by Min Liu in
Google Scholar
PubMed
Search for other papers by Zhe Chen in
Google Scholar
PubMed
Search for other papers by Yumei Jia in
Google Scholar
PubMed
Search for other papers by Guang Wang in
Google Scholar
PubMed
-mapping in identifying thyroid destruction in AIT patients. Subjects and methods Subjects This study is a case–control study. A total of 57 drug-naïve patients with AIT were recruited from the Endocrinology Department of Beijing Chao
Search for other papers by Marek Niedziela in
Google Scholar
PubMed
Cheng BW Lin CH Wu YL Hung CM Li HJ Long-term outcomes of Graves’ disease in children treated with anti-thyroid drugs . Pediatrics and Neonatology 2020 61 311 – 317 . ( https://doi.org/10.1016/j.pedneo.2019.12.009 ) 28 Harvengt J Boizeau
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Hanna Karhapää in
Google Scholar
PubMed
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Siru Mäkelä in
Google Scholar
PubMed
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Hanna Laurén in
Google Scholar
PubMed
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Marjut Jaakkola in
Google Scholar
PubMed
Endocrinology, Abdominal Centre, University of Helsinki and HUS, Helsinki, Finland
Search for other papers by Camilla Schalin-Jäntti in
Google Scholar
PubMed
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Micaela Hernberg in
Google Scholar
PubMed
immunotherapy drugs were lower than in our study. In another study with 99 advanced melanoma patients treated with pembrolizumab, the incidence of thyroid irAEs was slightly higher (17.1% vs 14% and 3%), but still a bit lower than in our study (25.7%) ( 24
Search for other papers by Xiao-Shan Huang in
Google Scholar
PubMed
Search for other papers by Ning Dai in
Google Scholar
PubMed
Search for other papers by Jian-Xia Xu in
Google Scholar
PubMed
Search for other papers by Jun-Yi Xiang in
Google Scholar
PubMed
Search for other papers by Xiao-Zhong Zheng in
Google Scholar
PubMed
Search for other papers by Tian-Yu Ke in
Google Scholar
PubMed
Search for other papers by Lin-Ying Ma in
Google Scholar
PubMed
Search for other papers by Qi-Hao Shi in
Google Scholar
PubMed
Search for other papers by Shu-Feng Fan in
Google Scholar
PubMed
pregnant, possibly pregnant, or taking medications known to affect thyroid function. All patients with HT were randomly assigned to two groups. The control group received a standard diet, while the low-carbohydrate diet group followed a low
Search for other papers by John E M Midgley in
Google Scholar
PubMed
Search for other papers by Rolf Larisch in
Google Scholar
PubMed
North Lakes Clinical, Department of Nuclear Medicine, Medical Department I, Ruhr Center for Rare Diseases (CeSER), 20 Wheatley Avenue, Ilkley LS29 8PT, UK
Search for other papers by Johannes W Dietrich in
Google Scholar
PubMed
Search for other papers by Rudolf Hoermann in
Google Scholar
PubMed
=9), anti-thyroid drug use ( n =99), hypothalamic/pituitary diseases ( n =5) or pregnancy ( n =3) were excluded before analysis. Diagnostic procedures included a detailed history, physical examination, standardised questionnaire documenting gender